scholarly journals Analysis of Copy Number Variations in Solid Tumors Using a Next Generation Sequencing Custom Panel

2021 ◽  
Vol 2 (2) ◽  
pp. 123-134
Author(s):  
Marta Vives-Usano ◽  
Beatriz García Pelaez ◽  
Ruth Román Lladó ◽  
Mónica Garzón Ibañez ◽  
Erika Aldeguer ◽  
...  

Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered the gold standard for CNV detection, the increasing number of potentially druggable amplifications to be assessed makes a gene-by-gene approach time- and tissue-consuming. Here we investigated the potential of next generation sequencing (NGS) custom panels to simultaneously determine CNVs across FFPE solid tumor samples. DNA was purified from cell lines and FFPE samples and analyzed by NGS sequencing using a 20-gene custom panel in the GeneReader Platform®. CNVs were identified using an in-house algorithm based on the UMI read coverage. Retrospective validation of in-house algorithm to identify CNVs showed 97.1% concordance rate with the NGS custom panel. The prospective analysis was performed in a cohort of 243 FFPE samples from patients arriving at our hospital, which included 74 NSCLC tumors, 148 CRC tumors, and 21 other tumors. Of them, 33% presented CNVs by NGS and in 14 cases (5.9%) the CNV was the only alteration detected. We have identified CNV alterations in about one-third of our cohort, including FGFR1, CDK6, CDK4, EGFR, MET, ERBB2, BRAF, or KRAS. Our work highlights the need to include CNV testing as a part of routine NGS analysis in order to uncover clinically relevant gene amplifications that can guide the selection of therapies.

2020 ◽  
Vol 33 (8) ◽  
pp. 1537-1545 ◽  
Author(s):  
Talha Anwar ◽  
Miguel L. Rufail ◽  
Sabra I. Djomehri ◽  
Maria E. Gonzalez ◽  
Lorena Lazo de la Vega ◽  
...  

2012 ◽  
Vol 40 (9) ◽  
pp. e69-e69 ◽  
Author(s):  
Günter Klambauer ◽  
Karin Schwarzbauer ◽  
Andreas Mayr ◽  
Djork-Arné Clevert ◽  
Andreas Mitterecker ◽  
...  

2020 ◽  
Vol 9 (1) ◽  
pp. 132 ◽  
Author(s):  
Rute Pereira ◽  
Jorge Oliveira ◽  
Mário Sousa

Clinical genetics has an important role in the healthcare system to provide a definitive diagnosis for many rare syndromes. It also can have an influence over genetics prevention, disease prognosis and assisting the selection of the best options of care/treatment for patients. Next-generation sequencing (NGS) has transformed clinical genetics making possible to analyze hundreds of genes at an unprecedented speed and at a lower price when comparing to conventional Sanger sequencing. Despite the growing literature concerning NGS in a clinical setting, this review aims to fill the gap that exists among (bio)informaticians, molecular geneticists and clinicians, by presenting a general overview of the NGS technology and workflow. First, we will review the current NGS platforms, focusing on the two main platforms Illumina and Ion Torrent, and discussing the major strong points and weaknesses intrinsic to each platform. Next, the NGS analytical bioinformatic pipelines are dissected, giving some emphasis to the algorithms commonly used to generate process data and to analyze sequence variants. Finally, the main challenges around NGS bioinformatics are placed in perspective for future developments. Even with the huge achievements made in NGS technology and bioinformatics, further improvements in bioinformatic algorithms are still required to deal with complex and genetically heterogeneous disorders.


Sign in / Sign up

Export Citation Format

Share Document